• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

REGiMMUNE Corporation

edit

REGiMMUNE Corporation is a biotechnology company focused on the discovery, development, and potential commercialization of immune-regulatory therapeutics to treat life-threatening diseases and debilitating disorders, including allergies, autoimmune and inflammatory disease. REGiMMUNE applies its reVax (reverse vaccination) technology and product development and clinical experience to generate, support and potentially commercialize a broad range of products for itself and its partners.

Recent Milestones

edit

• 
  REGiMMUNE Corporation received $6M in Series B funding. (2/1/08)
  Posted 12/19/09 at 1:09am via regimmune.com
• 
  REGiMMUNE Corporation received $4.2M in Series A funding. (2/21/07)
  Posted 3/16/10 at 11:29pm via regimmune.com
• 
  REGiMMUNE Corporation received $1.6M in Seed funding. (8/15/06)
  Posted 4/29/10 at 7:12pm via regimmune.com

Videos

Screenshots

edit

Above: REGiMMUNE Corporation
Uploaded: 12/19/09

Sources

1. Completed Seed Round Financing (regimmune.com) [edit]
2. REGiMMUNE Announces Series A Financing (regimmune.com) [edit]
3. REGiMMUNE Closes First Tranche of Series B Financing (regimmune.com) [edit]